Jason M. Foulks

Sumitomo Dainippon Pharma (United States) — United States

Immunology and Microbiology · Life Sciences

18h-index2.4kcitations144works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Phagocytosis and Immune Regulation(72), Pancreatic and Hepatic Oncology Research(37), CAR-T cell therapy research(33), Cancer Mechanisms and Therapy(20), Protein Degradation and Inhibitors(17)

Publications144 total

Supplementary Table S1 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Supplementary Figure Legends from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Supplementary Figures from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Supplementary Table S2 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study
Blood·2025Open Access
Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis
Blood·2025· 1 cited
Abstract A098: Nuvisertib shows single-agent anti-tumor activity in multiple myeloma nonclinical models
Molecular Cancer Therapeutics·2025
5-Azacytidine and decitabine induce C > G transversions in both murine and human cells
Leukemia·2025· 2 citedOpen Access
AXL promotes inflammatory breast cancer progression by regulating immunosuppressive macrophage polarization
Breast Cancer Research·2025· 4 citedOpen Access
Abstract 2989: PIM1 contributes to tumor progression, immune evasion and metastasis of triple-negative breast cancer
Cancer Research·2025
Abstract 2903: Evaluation of SMP-3124, a novel liposome-encapsulated CHK1 inhibitor, in patient-derived preclinical models of treatment-resistant ovarian cancer
Cancer Research·2025
Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients
Blood·2024· 1 cited
Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor
Blood·2024
A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis
Blood·2024· 2 cited
Supplementary Figure Legends from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Figure Legends from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Figures from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
page 1 of 8Next →

Frequent Co-authors

Steven L. Warner(24), Steven B. Kanner(11), Michael V. McCullar(9), David J. Bearss(8), Clifford J. Whatcott(8), Lars Mouritsen(8), Adrianne Clifford(7), Reona Sakemura(7), Mehrdad Hefazi(7), Michelle J. Cox(7), Kendall J. Schick(7), Sameer A. Parikh(7), Neil E. Kay(7), Saad S. Kenderian(7), Koc-Kan Ho(6), Sutapa Sinha(6), Michael J. Hansen(6), Justin C. Boysen(6), Renee C. Tschumper(6), Wei Ding(6)